Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
PDMR Transaction Notification
London, UK, 23 August 2021: Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Mr Anders Lundstrom, Non-Executive Director, acquired 10,000 Ordinary Shares in the Company on 20 August 2021 at an average price of $0.61 per share. Following the transaction, Mr Lundstrom has a beneficial interest in 10,000 shares.
The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a. | Name | Anders Lundstrom | ||||
| 2. | Reason for the notification | |||||
| a. | Position/status | Non-Executive Director | ||||
| b. | Initial notification /Amendment | Initial | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a. | Name | Shield Therapeutics plc | ||||
| b. | LEI | 213800G74QWY15FC3W71 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a. | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1.5p each in the capital of the Company
ISIN of Ordinary Shares: GB00BYV81293 | ||||
| b. | Nature of the transaction |
Acquisition of Ordinary Shares
| ||||
| c. | Price(s) and volume(s) |
| ||||
| d. | Aggregated information · Aggregated volume · Price
|
10,000
$6,100
| ||||
| e. | Date of the transaction | 2021-08-20 | ||||
| f. | Place of the transaction | OTCQX
| ||||
For further information, please contact:
| Shield Therapeutics plc | +44 (0) 191 511 8500 | ||
| Greg Madison (CEO) Hans-Peter Rudolf (CFO) | | ||
| | | ||
| Peel Hunt LLP - Nominated Adviser & Joint Broker | +44 (0) 20 7148 8900 | ||
| James Steel / Christopher Golden | | ||
| | | ||
| finnCap Ltd - Joint Broker | +44 (0) 20 7220 0500 | ||
| Geoff Nash / Alice Lane/ George Dollemore | | ||
|
|
| ||
| Walbrook PR - Financial PR & IR Adviser | +44 (0) 20 7933 8780 | ||
| Paul McManus / Lianne Cawthorne/ Alice Woodings | or shield@walbrookpr.com | ||
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer® in the US. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
